FDA slaps new bladder cancer limits on Merck's Keytruda, Roche's Tecentriq
admin 22nd June 2018 Uncategorised 0Last month, the FDA warned that immuno-oncology stars from Merck and Roche might actually be hurting some previously untreated bladder cancer patients’ survival chances. And now, it’s followed up by narrowing the drugs’ labels.
More: FDA slaps new bladder cancer limits on Merck's Keytruda, Roche's Tecentriq
Source: fierce